Archive for the ‘suit’ tag
Cambridge
Click here to see it on AdPharm
AdPharm is the largest online pharmaceutical advertising gallery. It is subscription-based with various subscriptions plans available here.
Caltrate Plus
Click here to see it on AdPharm
AdPharm is the largest online pharmaceutical advertising gallery. It is subscription-based with various subscriptions plans available here.
Olmetec and Olmetec Plus
Prenez le contrôle pour aider à la maîtrise de la T.A.
Olmetec – une puissance pour aider au contrôle de la T.A.
[Road sign] Maintenant sur la liste de médicaments du Québec.
Take charge to help control BP
Olmetec has power to help control BP.
[Road sign] Now on the Quebec list of medications
Brand name: Olmetec
Generic name/category: Olmesartan, Angiotensin II receptor antagonists (ARA – ARB), Imidazoles
Company: Schering-Plough
Country/Market: Canada, North America
Indication(s)/use: Hypertension, High Blood Pressure (HBP)
Target: Healthcare Professionals (HCP)
Tagline:
Prenez le contrôle pour aider à la maîtrise de la T.A.
Take charge to help control BP
Medium: Print ad
Size/duration: single-page
Publication/Aired: Le Patient – vol.3 no.3 – August 2009
To see all of this brand’s ads on AdPharm, click here
Alvesco print ads for HCPs in Canada in both French and English
Click on thumbnail to view the full-size ad on AdPharm
Click on thumbnail to view the full-size ad on AdPharm
Choisissez Alveso pour les enfants en pleine croissance.
Un traitement d’entretien de première intention de l’asthme sans aucun effet démontré sur la croissance. (tel que mesuré par le rythme de croissance et par stadiomètre au cours des essais cliniques).
Choose Alvesco for growing kids.
A first-line asthma maintenance therapy with no demonstrated effect on growth. (as measured by growth velocity and stadiometry in clinical trials).
Brand name: Alvesco
Generic name/category: Ciclesonide, Glucocorticoids
Company: Nycomed
Country/Market: Canada, North America
Indication(s)/use: Prophylactic management of steroid-responsive bronchial asthma in patients 6 years of age and older.
Target: Healthcare Professionals (HCP)
Tagline: Asthma control with confidence
Medium: Print ad
Size/duration: single-page
Publication/Aired: Le Médecin Du Québec and CMAJ – September 2009
To see all of this brand’s ads on AdPharm, click here
Olmetec and Olmetec Plus
| Take charge to help control BP Olmetec has power to help control BP. Olmesartan (trade names Benicar, Olmetec) is an angiotensin II receptor antagonist used to treat high blood pressure. The prodrug olmesartan medoxomil is marketed worldwide by Daiichi Sankyo, Ltd. and in the United States by Daiichi Sankyo, Inc. and Forest Laboratories. Olmesartan works by blocking the binding of angiotensin II to the AT1 receptors in vascular muscle; it is therefore independent of angiotensin II synthesis pathways, unlike ACE inhibitors. By blocking binding rather than synthesis of angiotensin II, olmesartan inhibits the negative regulatory feedback on renin secretion. As a result of this blockage, olmesartan reduces vasoconstriction and the secretion of aldosterone. This lowers blood pressure by producing vasodilation, and decreasing peripheral resistance. Olmesartan may possess high affinity for the Vitamin D Receptor, based on molecular modeling studies, but these results have not been duplicated in clinical trials. Because of the role of the Vitamin D receptor in innate immunity, this would indicate that olmesartan has immune modulatory properties. This theory is currently the premise underlying the Marshall Protocol, which uses olmesartan to impose a chemical blockade on 1,25 Vitamin D as part of a treatment of sarcoidosis and other diseases. The Marshall Protocol asserts that, assuming the etiology of these diseases is based on infection by cell-wall-deficient bacteria, restoring proper Vitamin D ratios via olmesartan dosing, combined with pulsed antibiotic dosing, would result in a cure. – Wikipedia Parkhurst Exchange April 2009 |
Olmetec and Olmetec Plus
Olmetec and Olmetec Plus Page 1 of 3
Pour aider à la maîtrise de la T.A., regardez droit devant
To help control High-blood pressure, look straight ahead.
Olmetec and Olmetec Plus Page 2 and 3 of 3
Prenez le contrôle pour aider à la maîtrise de la T.A.
Olmetec – une puissance pour aider au contrôle de la t.a.
Take charge to help control BP
Olmetec has power to help control BP.
Olmesartan (trade names Benicar, Olmetec) is an angiotensin II receptor antagonist used to treat high blood pressure. The prodrug olmesartan medoxomil is marketed worldwide by Daiichi Sankyo, Ltd. and in the United States by Daiichi Sankyo, Inc. and Forest Laboratories.
Olmesartan works by blocking the binding of angiotensin II to the AT1 receptors in vascular muscle; it is therefore independent of angiotensin II synthesis pathways, unlike ACE inhibitors. By blocking binding rather than synthesis of angiotensin II, olmesartan inhibits the negative regulatory feedback on renin secretion. As a result of this blockage, olmesartan reduces vasoconstriction and the secretion of aldosterone. This lowers blood pressure by producing vasodilation, and decreasing peripheral resistance.
Olmesartan may possess high affinity for the Vitamin D Receptor, based on molecular modeling studies, but these results have not been duplicated in clinical trials.
Because of the role of the Vitamin D receptor in innate immunity, this would indicate that olmesartan has immune modulatory properties. This theory is currently the premise underlying the Marshall Protocol, which uses olmesartan to impose a chemical blockade on 1,25 Vitamin D as part of a treatment of sarcoidosis and other diseases. The Marshall Protocol asserts that, assuming the etiology of these diseases is based on infection by cell-wall-deficient bacteria, restoring proper Vitamin D ratios via olmesartan dosing, combined with pulsed antibiotic dosing, would result in a cure. – Wikipedia
Le Médecin Du Québec April 2009
More cardiovascular-related ads on AdPharm
